Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants

  • 1. Zambrano LDEllington SAStrid Pet al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69:16411647

  • 2. DeSisto CLWallace BSimeone RMet al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization — United States, March 2020–September 2021. MMWR Morb Mortal Wkly Rep 2021;70:16401645

  • 3. Butt AAChemaitelly HAl Khal A, et al. SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. J Clin Invest 2021;131(23):e153662e153662

  • 4. Dagan NBarda NBiron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021;27:16931695

  • 5. Lip child HSVazquez-Benitez GDeSilva Met al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth — eight integrated health care organizations, United States, December 15, 2020–July 22, 2021. MMWR Morb Mortal Wkly Rep 2022;71:2630

  • 6. Shimabukuro TTKim SYMyers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med 2021;384:22732282

  • 7. Zauche LHWallace BSmoots AN, et al. Recipe of mRNA Covid-19 vaccines and risk of spontaneous abortion. N Engl J Med 2021;385:15331535

  • 8. Magnus MCGjessing HKEide HNWilcox AJFell DBHauberg SE† Covid-19 Vaccination during pregnancy and first-trimester miscarriage. N Engl J Med 2021;385:20082010

  • 9. Centers for Disease Control and Prevention. COVID-19 vaccines while pregnant or breastfeeding (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html).

  • 10. Abu Raya BEdwards KMScheifele DWHalperin SA† Pertussis and influenza immunization during pregnancy: a landscape review. Lancet Infect Dis 2017;17(7):e209e222

  • 11. Aziz-Baumgartner EGrohskopf LPatel M† Realizing the potential of maternal influenza vaccination. JAMA 2021;325:22572259

  • 12. Omer SB† Maternal immunization. N Engl J Med 2017;376:12561267

  • 13. Halasa NBOlson SMState MAet al. Effectiveness of maternal vaccination with mRNA COVID-19 vaccine during pregnancy against COVID-19-associated hospitalization in infants aged <6 months — 17 states, July 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:264270

  • 14. Carlsen EØMagnus MCOakley L, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med 2022 June 1 (Epub ahead of print).

  • 15. Mithal LBAOtero SShanes EDGoldstein YESMiller ES† Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol 2021;225:192194

  • 16. Beharier OPlitman Mayo RRaz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest 2021;131:150319150319

  • 17. Prabhu MMurphy EASukhu AC, et al. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol 2021;138:278280

  • 18. Perl SHUzan-Yulzari AKlainer H, et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA 2021;325:20132014

  • 19. Baird JKJensen SMUrba WJFox BABaird JR† SARS-CoV-2 antibodies detected in mother’s milk post-vaccination. J Hum Lact 2021;37:492498

  • 20. Yang YJMurphy EASingh S, et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery . Obstet Gynecol 2022;139:373380

  • 21. Trostle MEAguero-Rosenfeld MERoman ASLighter JL† High antibody levels in cord blood from pregnant women vaccinated against COVID-19. Am J Obstet Gynecol MFM 2021;3:100481100481

  • 22. Nir OSchwartz AToussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol MFM 2022;4:100492100492

  • 23. shook LLAtyeo CGYonker LM, et al. Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection. JAMA 2022;327:10871089

  • 24. Marks KJWhitaker MAgathis NTet al. Hospitalization of infants and children aged 0-4 years with laboratory-confirmed COVID-19 — COVID-NET, 14 states, March 2020–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:429436

  • 25. Hobbs CVWoodworth KYoung CC, et al. Frequency, characteristics and complications of COVID-19 in hospitalized infants. Pediatr Infect Dis J 2022;41(3):e81e86

  • 26. Mølgaard-Nielsen DFischer TKKrause TGHviid A† Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants. J Intern Med 2019;286:469480

  • 27. Olson SMNewham’s MMHalasa NB, et al. Vaccine effectiveness against life-threatening influenza illness in US Children. Clin Infect Dis 2022 January 13 (Epub ahead of print).

  • 28. Chua Hofeng sLewnard YES, et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology 2020;31:4364

  • 29. Olson SMNewham’s MMHalasa NB, et al. Effectiveness of BNT162b2 vaccine against Critical Covid-19 in adolescents. N Engl J Med 2022;386:713723

  • 30. Olson SMNewham’s MMHalasa NBet al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years — United States, June–September 2021. MMWR Morb Mortal Wkly Rep 2021;70:14831488

  • 31. Office of the Federal Register. Code of federal regulations: a point in time eCFR system. Title 45 (https://www.ecfr.gov/cgi-bin/text-idx?SID=fc043bd2812f0775fa80066558a6bbcf&mc=true&node=pt45.1.46&rgn=div5#se45.1.46_1102).

  • 32. Razzaghi HMeghani MPingali Cet al. COVID-19 vaccination coverage among pregnant women during pregnancy — eight integrated health care organizations, United States, December 14, 2020–May 8, 2021. MMWR Morb Mortal Wkly Rep 2021;70:895899

  • 33. Patel MKBergeri IBresee JSO, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance from the World Health Organization. Vaccine 2021;39:40134024

  • 34. Centers for Disease Control and Prevention. COVID data tracker: variant proportions (https://covid.cdc.gov/covid-data-tracker/#variant-proportions).

  • 35. Gray KJBordt EAAtyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021;225(3):303.e1303.e17

  • 36. Small POIStockwell MSDemarco Met al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years — VISION Network, 10 States, April 2021– January 2022. MMWR Morb Mortal Wkly Rep 2022;71:352358

  • 37. Lauren ASTenforde MWChappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, Covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022;376:e069761e069761

  • 38. Centers for Disease Control and Prevention. Archived cumulative data: percent of pregnant people aged 18-49 years receiving at least one dose of a COVID-19 vaccine during pregnancy overall, by race/ethnicity, and date reported to CDC-Vaccine Safety Datalink*, United States | December 20, 2020–January 20, 2022 (https://data.cdc.gov/Vaccinations/Cumulative-Data-Percent-of-Pregnant-People-aged-18/4ht3-nbmd/data).

  • 39. Nemet IClicker Llusty Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med 2022;386:492494

  • 40. Thompson MGNatarajan KIrving SAet al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:139145

  • Leave a Comment